Saturday, May 21, 2022
HomeLatest Pharma-NewsImmunomedics Resubmits Biologics License Application to FDA for the treatment of...

Immunomedics Resubmits Biologics License Application to FDA for the treatment of metastatic triple-negative breast cancer (mTNBC)

Dec. 03, 2019: Immunomedics,a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC) announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in quest of accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC).

If sacituzumab govitecan approved, it could become an important new treatment option for patients with late-stage mTNBC. https://fda.einnews.com/pr_news/503880625/immunomedics-resubmits-biologics-license-application-to-the-fda-for-sacituzumab-govitecan

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular